Joint research starting immediately on Alzheimer’s, Parkinson’s, schizophrenia, geriatric psychiatry, as well as neurological diseases that are unique to the Jewish population

KAHR's leading drug candidate, now in clinical trials, is based on a compound that targets cancer cells, weakens their defenses and activates a local immune response

Products help medical professionals analyze data and gain insight into patients' needs; collaboration program to be expanded to other medical centers